Evidence map›Paper›PMID 25838436›Full record

ReviewEuropean heart journal2015

The kidney in heart failure: an update.

Kevin Damman, Jeffrey M Testani

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 231 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298229 phase3completedstarted 2020, after this paper: background citation

A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure

Ran2020Enrolled240Registered outcomes3Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Heart FailureArmsDapagliflozin 10 mg, Protocolized Diuretic Therapy
PMID 27266853PMID 26299229PMID 26041600PMID 25287144PMID 24879974PMID 24585267PMID 24379278PMID 24247300PMID 23356556PMID 23333145PMID 23141816PMID 21732835other papers from this trial
Open the trial in the graph
NCT03863626 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Exploring Diuretics Effective Management in Acute Decompensated Heart Failure, EDEMA Trial

TypeinterventionalSponsorCairo UniversityRan2019 to 2021Enrolled400ConditionsAcute Decompensated Heart Failure, Diuretics ResistanceArmsFrusemide IV shots, Frusemide IV infusion
3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Early discharge after clinical stabilization in acute decompensated heart failure: associations with short-term outcomes.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  13. Review
  14. Longitudinal Endothelial Activation and Stress Index (EASIX) trajectories and mortality risk in chronic heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kevin DammanUniversity of Groningen, Department of Cardiology, University Medical Center Groningen, Hanzeplein 1, 9700RB Groningen, The Netherlands k.damman@umcg.nl.
Jeffrey M TestaniDepartment of Internal Medicine and Program of Applied Translational Research, Yale University, New Haven, CT, USA.

Funding

Cardio-renal phenotype and prognosis in chronic heart failureK23HL114868 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2012 to 2017
$845k
NHLBI NIH HHS K23 HL114868NHLBI NIH HHS K23HL114868NHLBI NIH HHS L30HL115790
6 · The paper itself

Abstract

Heart and kidney are closely related in the clinical syndrome of heart failure (HF). It is now sufficiently clear that renal dysfunction occurs frequently in all phenotypes of HF, and when present, it is associated with higher mortality and morbidity. While the pathophysiology is multifactorial, the most important factors are a reduced renal perfusion and venous congestion. Recent interest has focused on worsening renal function (WRF), a situation strongly related to mortality, but seemingly only when HF status deteriorates. Unfortunately, to date clinicians are unable to identify specifically those patients with a grim prognosis following WRF. Although much has been learned on cardiorenal interaction in HF, still more questions have been left unanswered. The coming decade should provide us with more dedicated epidemiologic, mechanistic, and controlled trials in HF patients with reduced renal function. An updated classification of the cardiorenal syndrome that incorporates recent evidence and points towards areas of interest and uncertainties, and areas where progress is needed could facilitate this process. Ultimately, this should lead to preventive and treatment strategies that can preserve renal function and associated outcome in patients with HF.

Indexed as

Acute Kidney InjuryBiomarkersCardio-Renal SyndromeEarly DiagnosisForecastingGlomerular Filtration RateHemodynamicsHumansKidney Failure, ChronicMeta-Analysis as TopicPrognosisTerminology as TopicBiomarkersCardiorenal interactionHeart failureRenal dysfunction

Identifiers

PMID25838436
PMCPMC4465636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.